Fig. 8: Dimenhydrinate has therapeutic efficacy against cancer and 5-FU chemotherapy-induced sarcopenia without promoting tumorigenesis. | Experimental & Molecular Medicine

Fig. 8: Dimenhydrinate has therapeutic efficacy against cancer and 5-FU chemotherapy-induced sarcopenia without promoting tumorigenesis.

From: Transcriptome-based deep learning analysis identifies drug candidates targeting protein synthesis and autophagy for the treatment of muscle wasting disorder

Fig. 8

a Schematic representation of the overall schedule for assessing the therapeutic effect of DH (50 mpk) on cancer model mice and 5-FU chemotherapy-induced model mice. b Representative MR images for fat volume measurement (highlighted in red). c Representative MR images for muscle volume measurement (highlighted in red). d Graphical representation of body weight measurements for each group over time. e Relative change in body weight between day 18 and day 8 for each group. f Graph of tumor size measurements for each group over time. g Relative tumor volume for each group. h Graph of muscle volume measurements for each group over time. i Relative change in muscle volume between day 18 and day 8 in each group; n = 8. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.005. Error bars: standard deviation (SD). DH dimenhydrinate.

Back to article page